RRM2B

Across TCGA pan-cancer cohorts, RRM2B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RRM2B’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RRM2B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RRM2B is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

LIHC, HNSC, and LUSC are the cancer types where RRM2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RRM2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	III,IV	+1.180	<.001	9	view →
HNSC	Female	All	+0.885	<.001	8	view →
LUSC	Female	All	−0.835	<.001	8	view →
STAD	All	II,III,IV	+0.856	<.001	6	view →
LUAD	Female	II,III,IV	−0.710	<.001	6	view →
CHOL	All	All	+1.058	.003	4	view →
BRCA	All	II,III,IV	+0.475	<.001	4	view →
KIRP	Female	II,III,IV	+1.044	.017	2	view →
KICH	All	All	−0.576	.013	2	view →
BLCA	All	All	+0.451	.040	2	view →
PAAD	Male	All	+0.314	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RRM2B–LIHC

Open the LIHC breakdown →